Through a series of events in early 2011, the founders of Lyra Medical, understood the depth of the challenge associated with one of the most common issues affecting millions of women across the world; Pelvic Organ Prolapse (POP).
About Lyra Medical
A COMMON ISSUE
AN EXPERT SOLUTION
The company’s in-depth research shed light not only on the complications associated with existing solutions, but more importantly, their cause. Lyra leveraged the expertise of its team in the field of medical devices and clinical practice, to create a safe, reliable solution that would improve the treatment of POP and the lives of women affected by it.
thorough TESTING
With a desire to create a solution that would meet the highest standards, Lyra followed the best research practice, strictly and precisely. The Self-Retaining Support (SRS) concept was initially tested in a series of cadaver and animal studies, before progressing to large-scale clinical trials. The result is a seemingly simple solution, but one that provides a safe and effective long-term treatment for POP, which far surpasses any other treatment available today.
A RISING SUCCESS
Lyra has already achieved a robust IP portfolio, including approved US and EU patents, with several others pending for new applications. The company is privately owned, with research and development facilities and headquarters in Israel. Having secured mass-production capabilities, an international distribution agreement, training facilities throughout Europe, and a growing market share in Europe and Israel, Lyra is well on its way to revolutionizing the treatment of POP.